Cargando…

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers

OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have si...

Descripción completa

Detalles Bibliográficos
Autores principales: Konoshita, Tadashi, Kato, Norihiro, Fuchs, Sébastien, Mizuno, Shinichi, Aoyama, Chikako, Motomura, Makoto, Makino, Yasukazu, Wakahara, Shigeyuki, Inoki, Isao, Miyamori, Isamu, Pinet, Florence
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713645/
https://www.ncbi.nlm.nih.gov/pubmed/19509012
http://dx.doi.org/10.2337/dc09-0348
_version_ 1782169594747682816
author Konoshita, Tadashi
Kato, Norihiro
Fuchs, Sébastien
Mizuno, Shinichi
Aoyama, Chikako
Motomura, Makoto
Makino, Yasukazu
Wakahara, Shigeyuki
Inoki, Isao
Miyamori, Isamu
Pinet, Florence
author_facet Konoshita, Tadashi
Kato, Norihiro
Fuchs, Sébastien
Mizuno, Shinichi
Aoyama, Chikako
Motomura, Makoto
Makino, Yasukazu
Wakahara, Shigeyuki
Inoki, Isao
Miyamori, Isamu
Pinet, Florence
author_sort Konoshita, Tadashi
collection PubMed
description OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have significant impacts on the response to ARBs. RESEARCH DESIGN AND METHODS: Subjects comprised 231 consecutively enrolled hypertensive individuals including 45 type 2 diabetic subjects. Five genetic variants of the RAS, i.e., renin (REN) C-5312T, ACE insertion/deletion, angiotensinogen M235T, angiotensin II type 1 receptor A1166C, and angiotensin II type 2 receptor C3123A were assayed by PCR and restriction fragment-length polymorphism. A dose of 40–160 mg/day of valsartan was administered for 3 months as a monotherapy. RESULTS: Changes in diastolic blood pressure significantly differed between genotypes of REN C-5312T: 10.7-mmHg reduction (from 95.9 ± 12.9 to 85.2 ± 11.4) in CC versus 7.0-mmHg reduction (from 94.7 ± 14.0 to 87.7 ± 12.6) in CT/TT (P = 0.02 for interactive effects of valsartan and genotype). Responder rates also differed between the genotypes: 72.8% in CC versus 58.0% in CT/TT (P = 0.03). Univariate analysis indicated a significant association of response to valsartan with blood pressure, diabetes, plasma aldosterone concentration, and CC homozygotes of REN C-5312T. Finally, multiple logistic regression analysis revealed that systolic blood pressure, CC homozygotes of REN C-5312T, and diabetes were independent predictors for responders with odds ratios (95% CI) of 2.49 (1.41–4.42), 2.03 (1.10–3.74), and 0.48 (0.24–0.96), respectively. CONCLUSIONS: This study provides strong support that a genetic variant of REN C-5312T and diabetes contribute to the effects of ARBs and are independent predictors for responder. Thus, in treatment of hypertension with ARBs, a new possibility for personalized medicine has been shown.
format Text
id pubmed-2713645
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-27136452010-08-01 Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers Konoshita, Tadashi Kato, Norihiro Fuchs, Sébastien Mizuno, Shinichi Aoyama, Chikako Motomura, Makoto Makino, Yasukazu Wakahara, Shigeyuki Inoki, Isao Miyamori, Isamu Pinet, Florence Diabetes Care Original Research OBJECTIVE: Recent studies have proven the favorable effects of angiotensin receptor blockers (ARBs) on cardiovascular and renal disorders. However, determinants of the response to ARBs remain unclear. We substantiated the hypothesis that genetic variants of the renin-angiotensin system (RAS) have significant impacts on the response to ARBs. RESEARCH DESIGN AND METHODS: Subjects comprised 231 consecutively enrolled hypertensive individuals including 45 type 2 diabetic subjects. Five genetic variants of the RAS, i.e., renin (REN) C-5312T, ACE insertion/deletion, angiotensinogen M235T, angiotensin II type 1 receptor A1166C, and angiotensin II type 2 receptor C3123A were assayed by PCR and restriction fragment-length polymorphism. A dose of 40–160 mg/day of valsartan was administered for 3 months as a monotherapy. RESULTS: Changes in diastolic blood pressure significantly differed between genotypes of REN C-5312T: 10.7-mmHg reduction (from 95.9 ± 12.9 to 85.2 ± 11.4) in CC versus 7.0-mmHg reduction (from 94.7 ± 14.0 to 87.7 ± 12.6) in CT/TT (P = 0.02 for interactive effects of valsartan and genotype). Responder rates also differed between the genotypes: 72.8% in CC versus 58.0% in CT/TT (P = 0.03). Univariate analysis indicated a significant association of response to valsartan with blood pressure, diabetes, plasma aldosterone concentration, and CC homozygotes of REN C-5312T. Finally, multiple logistic regression analysis revealed that systolic blood pressure, CC homozygotes of REN C-5312T, and diabetes were independent predictors for responders with odds ratios (95% CI) of 2.49 (1.41–4.42), 2.03 (1.10–3.74), and 0.48 (0.24–0.96), respectively. CONCLUSIONS: This study provides strong support that a genetic variant of REN C-5312T and diabetes contribute to the effects of ARBs and are independent predictors for responder. Thus, in treatment of hypertension with ARBs, a new possibility for personalized medicine has been shown. American Diabetes Association 2009-08 2009-06-09 /pmc/articles/PMC2713645/ /pubmed/19509012 http://dx.doi.org/10.2337/dc09-0348 Text en © 2009 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Konoshita, Tadashi
Kato, Norihiro
Fuchs, Sébastien
Mizuno, Shinichi
Aoyama, Chikako
Motomura, Makoto
Makino, Yasukazu
Wakahara, Shigeyuki
Inoki, Isao
Miyamori, Isamu
Pinet, Florence
Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title_full Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title_fullStr Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title_full_unstemmed Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title_short Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
title_sort genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713645/
https://www.ncbi.nlm.nih.gov/pubmed/19509012
http://dx.doi.org/10.2337/dc09-0348
work_keys_str_mv AT konoshitatadashi geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT katonorihiro geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT fuchssebastien geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT mizunoshinichi geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT aoyamachikako geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT motomuramakoto geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT makinoyasukazu geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT wakaharashigeyuki geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT inokiisao geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT miyamoriisamu geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT pinetflorence geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers
AT geneticvariantofthereninangiotensinsystemanddiabetesinfluencesbloodpressureresponsetoangiotensinreceptorblockers